Grace Crotty, MD

Project Title: “The role of metabolomics in predicting LRRK2 gene mutation’s presence and penetrance in Parkinson’s disease”

Parkinson’s disease (PD) is the second most common neurodegenerative disorder and the fastest growing neurological disorder in terms of prevalence, disability, and deaths. However, there are currently no disease-modifying therapies available for this condition. Mutations in the LRRK2 gene have been considered a causative factor in PD, however, not all carriers of this gene develop PD.

Dr. Crotty’s research will use metabolomics – an emerging, powerful tool for studying large-scale data and information – in individuals with the LRRK2 mutation. This research may provide insight into the underlying molecular sources and causes of PD, and will allow researchers to better identify potential biomarkers for identifying and treating PD.

Dr. Crotty is an instructor in neurology at Massachusetts General Hospital.

This research is funded by the Parkinson’s Foundation and the American Brain Foundation, in collaboration with the American Academy of Neurology.